All PlansAdministrativeHigh impact
Voluntary nationwide recall: Famotidine (Fresenius – November)
UPMC Health Plan·Gastroenterology, Internal Medicine, Family Medicine +3 more·Pharmacy
We identified it
Jun 20, 2026
Summary
Fresenius Kabi is recalling three lots of Famotidine Injection due to elevated endotoxin levels that may cause serious adverse reactions including sepsis and death. Healthcare providers must immediately stop using the recalled lots and contact patients who may have received them.
Action Required
Immediately: Clinical staff must identify any inventory of recalled Famotidine Injection lots (6133156, 6133194, and 6133388) and remove from use. Contact all patients who received these lots since the recall announcement. Providers should document any adverse reactions and report to Fresenius Kabi Quality Assurance at 866-716-2459. Billing team should flag any recent claims for Famotidine administration for potential review.